ArticleBMJ open2026

Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study.

Ingrid Charlotte Kongerud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.